BiologicsMD, Inc. Announces Issuance of First U.S. Patent for PTH-CBD™
PTH-CBD™ Composition of Matter Patent Issued in the United States – Additional Worldwide Patents Pending
FAYETTEVILLE, Ark.– August 15, 2013 – BiologicsMD, Inc., a privately held drug discovery company developing unique biologic therapeutics for improving bone health, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,450,273, entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone," to The Board of Trustees of the University of Arkansas (U.S.), the Ochsner Clinic Foundation (U.S.) and the National University Corporation Kagawa University (Japan). BiologicsMD™ is the exclusive licensee of the patent. The patent claims various forms of composition of matter for the proteins derived by the fusion between collagen-binding polypeptides bound to parathyroid hormone receptor agonists.
BiologicsMD is developing PTH-CBD™ as a novel and unique treatment for osteoporosis and other bone-related disorders.The technology originated in the laboratories of Joshua Sakon, Ph.D. (University Of Arkansas), Robert Gensure, M.D., Ph.D. (previously with the Ochsner Clinic and currently with Montefiore Medical Center, NYC) and Osamu Matsushita, Ph.D. (previously with Kagawa University and currently with Okayama University).
"This is the first U.S. patent to issue from a patent family related to PTH-CBD and its use in treating diseases of the bone and other collagen-related disorders," stated J. David Owens, Chief Executive Officer of BiologicsMD. "PTH-CBD has pending methods patent applications in the U.S., along with patents being pursued in major worldwide markets. Because of PTH-CBD's unique profile of selective targeting and other pharmacologic properties, we foresee a highly differentiated new product to help treat human disease."